Read Time:24 Second
The Metanova Labs team, Micaela Bazo and Penn Apdr, discuss how their subnet is decentralizing drug discovery through AI-driven molecular screening. They explore upstream determinants of health, neuroplasticity, and strategic therapeutic targets like monoamine transporters and HDACs. The conversation also covers intellectual property in decentralized science, miner incentives, and the launch of NOVA Blueprint as a new framework for collaborative pharmaceutical innovation.
Great interview by Subnet Magazine’s team!
Check it here:
Be the first to comment